GLP-1 & compounded medication availability in Arizona (2026)

Arizona wrote one of the country’s most explicit telehealth frameworks into state law, and that framework is why ordering compounded medication from home works smoothly here. Below is the full ten-line picture for Arizona addresses: what ships, what doesn’t, and the specific state rules that govern both, each claim linked to the rule it rests on.

Baseline state

Availability facts last reviewed: November 16, 2026

The ten-line picture for Arizona

Availability of all ten OrderlyMeds product lines in Arizona, with typical delivery times and notes
Product lineAvailable in Arizona?Typical deliveryNotes
GLP-1 (compounded semaglutide) Yes 8–10 business days Ships to every Arizona address we serve; dosing is set by your prescriber.
GLP-1/GIP (compounded tirzepatide) Yes 8–10 business days Same flat national price at each dose tier.
NAD+ Yes 8–10 business days Fulfilled by licensed partner pharmacies holding Arizona permits.
Sermorelin Yes 8–10 business days Ordered through the same eligibility flow as every other line.
Glutathione No N/A Not part of the current OrderlyMeds formulary.
BPC-157 Yes 8–10 business days A compounded injectable here. Its own federal record is below.
TB-500 Yes 8–10 business days Compounded injectable; its federal section below is required reading.
KPV No N/A Not carried in any state, because our peptide formulary is injectable-only.
Epitalon Yes 8–10 business days Compounded injectable; see the cited federal facts beneath this table.
MOTS-c Yes 8–10 business days Compounded injectable with a federal record distinct from its siblings.

Every “No” above is deliberate data, not a missing row. Arizona entries were last reviewed November 16, 2026.

Research peptides in Arizona: BPC-157, TB-500, KPV, Epitalon & MOTS-c

Of these five peptides, OrderlyMeds carries four for Arizona addresses: BPC-157, TB-500, Epitalon and MOTS-c, each as a compounded injectable dispensed on a patient-specific prescription. KPV is the exception: our peptide formulary is injectable-only, and KPV is not compounded that way. What follows is each substance’s own federal record, stated whether or not the line ships to you, because these five do not share a single story and a buyer in Arizona deserves the specifics.

BPC-157 in Arizona

Carried for Arizona as a compounded injectable on a patient-specific prescription. Its federal record:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500 in Arizona

In the Arizona formulary as a compounded injectable, patient-specific prescription required. The two federal facts:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV in Arizona

Not shipped to Arizona or anywhere else, because KPV sits outside our injectable-only peptide formulary.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon in Arizona

Available to Arizona addresses as a compounded injectable under a patient-specific prescription. Federally:

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c in Arizona

Ships to Arizona as a compounded injectable, patient-specific prescription required. Its record is its own, not a copy of the other four:

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

What Arizona’s pharmacy and telehealth rules actually say

Arizona’s approach is licensure-first and unusually telehealth-forward. The state regulates who may ship medication to its residents and who may examine and write for them remotely, and it put the telehealth half directly into state law rather than leaving it to case-by-case board interpretation. For an Arizona patient, three cited rules below cover the whole journey: the pharmacy’s permit, the provider’s authority to evaluate you remotely, and the registration path that lets an out-of-state provider do so.

Arizona requires each facility outside the state that will dispense, sell, transfer or distribute drugs into Arizona to hold a permit from the state’s pharmacy regulator, under A.R.S. § 32-1929. Source: Arizona Revised Statutes § 32-1929.

Arizona telehealth law bars requiring an in-person examination before a prescription may be issued (Schedule II controlled substances excepted — none of the medications on this page is one); a telehealth encounter meeting the standard of care suffices. A.R.S. § 36-3602(E). Source: Arizona Revised Statutes § 36-3602.

A provider located outside Arizona may deliver telehealth services to patients in the state by registering with the applicable Arizona health-profession regulator, if the provider holds a current, unrestricted and substantially similar license in another state. A.R.S. § 36-3606. Source: Arizona Revised Statutes § 36-3606.

The Arizona State Board of Pharmacy has published no semaglutide-, tirzepatide- or peptide-specific compounding restriction; compounding into and within Arizona runs on the standard permit system above plus the federal 503A/503B framework. Source: Arizona State Board of Pharmacy.

Put together, an Arizona order is as close to friction-free as this family of medications gets: a remote evaluation is expressly contemplated by state law, the pharmacies filling it hold Arizona permits, and no product line on this page carries an Arizona-specific restriction beyond that. Pricing does not change at the state line. What our pricing page shows is what Phoenix, Tucson and Flagstaff all pay.

Arizona availability FAQs

Can I get compounded semaglutide in Arizona?

Yes. OrderlyMeds ships compounded semaglutide to Arizona addresses from partner pharmacies permitted for the state, starting at $74/month for the first two months for new customers.

Does Arizona make telehealth prescribing harder than other states?

The opposite: state law expressly bars conditioning a prescription on an in-person visit for medications like these, and it gives out-of-state providers a registration path. The regulator section above links the exact sections.

Which research peptides actually ship to Arizona?

BPC-157, TB-500, Epitalon and MOTS-c, each as a compounded injectable on a patient-specific prescription. KPV is not in our formulary in any state. Each line’s own federal record is stated in full above.

How long until an Arizona order arrives?

Plan on 8–10 business days from signup. That is our published window nationally, and Arizona orders track it.

Keep exploring

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone